Cancer Therapy

You have full text access to this OnlineOpen article

Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO–PCV chemotherapy

  1. Victor A. Levin1,†,*,
  2. Jacob L. Jochec1,
  3. Lisa M. Shantz3,
  4. Kenneth D. Aldape2

Article first published online: 20 JUN 2007

DOI: 10.1002/ijc.22914

Issue

International Journal of Cancer

International Journal of Cancer

Volume 121, Issue 10, pages 2279–2283, 15 November 2007

Additional Information

How to Cite

Levin, V. A., Jochec, J. L., Shantz, L. M. and Aldape, K. D. (2007), Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO–PCV chemotherapy. Int. J. Cancer, 121: 2279–2283. doi: 10.1002/ijc.22914

Author Information

  1. 1

    Department of Neuro-Oncology and M. D. Anderson Clinical Oncology Program, The University of Texas M. D. Anderson Cancer Center, Houston, TX

  2. 2

    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

  3. 3

    Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, PA

  1. †

    Victor A. Levin is a founder of VBL Pharmaceuticals Inc., a company that intends to seek United States FDA approval for DFMO in the treatment of anaplastic gliomas.

*Department of Neuro-Oncology, Unit 431, The University of Texas M. D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402, USA

Publication History

  1. Issue published online: 25 SEP 2007
  2. Article first published online: 20 JUN 2007
  3. Manuscript Accepted: 4 MAY 2007
  4. Manuscript Received: 30 MAR 2007

Funded by

  • Commonwealth Foundation for Cancer Research
  • NIH. Grant Numbers: CA 82768, U10 CA 45809

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (146K)

References

  • 1
    Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998; 4: 1661–72.
  • 2
    Hochhaus A, Lahaye T, Kreil S, Berger U, Metzgeroth G, Hehlmann R. Selective inhibition of tyrosine kinases—a new therapeutic principle in oncology. Onkologie 2001; 24: 65–71.
  • 3
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–109.
  • 4
    Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133–44.
  • 5
    Levin VA, Chamberlain MC, Prados MD, Choucair AK, Berger MS, Silver P, Seager M, Gutin PH, Davis RL, Wilson CB. Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat Rep 1987; 71: 459–64.
  • 6
    Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 1992; 84: 1432–7.
  • 7
    Prados M, Rodriguez L, Chamberlain M, Silver P, Levin VA. Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosoureaand alpha-difluoromethylornithine. Neurosurgery 1989; 24: 806–9.
  • 8
    Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO–PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000; 6: 3878–84.
  • 9
    Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003; 9: 981–90.
  • 10
    Levin VA, Jochec JL, Shantz LM, Koch PE, Pegg AE. Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine. J Histochem Cytochem 2004; 52: 1467–74.
  • 11
    Shantz LM, Pegg AE. Ornithine decarboxylase induction in transformation by H-Ras and RhoA. Cancer Res 1998; 58: 2748–53.
  • 12
    Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 1998; 4: 117–30.
  • 13
    Shantz LM, Feith DJ, Pegg AE. Targeted overexpression of ornithine decarboxylase enhances beta-adrenergic ag onist-induced cardiac hypertrophy. Biochem J 2001; 358: 25–32.
View Full Article (HTML) Get PDF (146K)